172 related articles for article (PubMed ID: 31072612)
41. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
Mar N; Vredenburgh JJ
Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
[TBL] [Abstract][Full Text] [Related]
42. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
[TBL] [Abstract][Full Text] [Related]
43. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
[TBL] [Abstract][Full Text] [Related]
45. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
46. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasąg B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S
J Thorac Oncol; 2019 Jun; 14(6):1086-1094. PubMed ID: 30825613
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
[TBL] [Abstract][Full Text] [Related]
48. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.
Suzuki M; Shigematsu H; Hiroshima K; Iizasa T; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Hum Pathol; 2005 Oct; 36(10):1127-34. PubMed ID: 16226114
[TBL] [Abstract][Full Text] [Related]
49. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
50. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
[TBL] [Abstract][Full Text] [Related]
51. HER2 and lung cancer.
Landi L; Cappuzzo F
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
[TBL] [Abstract][Full Text] [Related]
52. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
53. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
54. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.
Ludovini V; Flacco A; Bianconi F; Ragusa M; Vannucci J; Bellezza G; Chiari R; Minotti V; Pistola L; Tofanetti FR; Siggillino A; Baldelli E; Sidoni A; Daddi N; Puma F; Varella-Garcia M; Crinò L
Cancer Chemother Pharmacol; 2013 Mar; 71(3):671-80. PubMed ID: 23314677
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
56. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
57. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
58. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
59. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
60. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
